Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
Information on the EAMS scientific opinion given to nivolumab for renal cell carcinoma (RCC), including the public assessment report.